You are here

Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents

Last updated on December 16, 2017

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Growth Hormone Deficiency
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
15-20 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Males or females : Chronological age > or = 15 years and

- Chronological age > or = 17 years and

- GHD of childhood onset treated for at least 2 years

- Last GH injection at least 12 months before baseline visit

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Turner's syndrome

- Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN

NCT00156143
Pfizer
Completed
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
NCT02319837
Males
18+
Years
Multiple Sites
Prostate Cancer, Hormone Refractory Prostate Cancer
NCT00510718
Males
0+
Years
Multiple Sites
Vascular Endothelial Growth Factor, Macular Degeneration
NCT00735943
All Genders
18+
Years
Multiple Sites
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Growth Hormone Deficiency
  • Procedure: Blood sample
  • Procedure: Radiography
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
90
April 2005
Not Provided

Inclusion Criteria:

  • Males or females : Chronological age > or = 15 years and < or = 20 years for females
  • Chronological age > or = 17 years and < or = 20 years for males
  • GHD of childhood onset treated for at least 2 years
  • Last GH injection at least 12 months before baseline visit

Exclusion Criteria:

  • Turner's syndrome
  • Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN
Sexes Eligible for Study: All
15 Years to 20 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
France
 
NCT00156143
307-MET-9002-016
A6281018
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2007

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now